Related coverage linked through entity extraction aliases.
Apr 24, 2026
A longitudinal study of 460,000 teenagers found adolescent cannabis use was linked to higher risks of later bipolar, psychotic, anxiety and depression diagnoses. Separate research and expert guidance say THC effects, especially long term, still need more study.
Apr 22, 2026
Diabetes and heart disease can impair sexual function by damaging blood vessels, nerves and circulation. Sexual dysfunction may also be an early warning sign of underlying vascular damage.
Apr 05, 2026
Neumora said it plans higher-dose NMRA-511 work in 2026 and pivotal studies in 2027 after additional phase 1b analyses in Alzheimer’s disease agitation. The company also scheduled its fourth-quarter and full-year 2025 financial results update for March 30, 2026.
Apr 05, 2026
Studies of psilocybin found lasting shifts in life values in healthy volunteers and reduced fear of death in therapeutic settings. Trials have also reported benefits in cancer patients.
Apr 02, 2026
A 16-year study links higher vitamin D levels in middle age to lower tau protein deposits in the brain, while a major COVID-19 trial finds vitamin D doesn't reduce acute severity but may help with long COVID recovery. Separate research shows supplementation improves vitamin D levels and stabilizes immune profiles in athletes and non-athletes.
Mar 25, 2026
Clinical trials show psychedelic substances like psilocybin, LSD and MDMA combined with therapy can effectively treat depression, anxiety and addiction. Several substances are in Phase III trials, with esketamine already approved for treatment-resistant depression. Research suggests these treatments may work with fewer doses than traditional medications.
Mar 24, 2026
A study of 1.9 million births in Sweden found new fathers have a 30% increased risk of depression and anxiety disorders by their baby's first birthday. The research highlights the need for better mental health screening and support for fathers during the postpartum period.
Mar 13, 2026
Bunnie Xo, wife of country star Jelly Roll, revealed she experienced suicidal thoughts while taking semaglutide, describing December 2025 as "one of the darkest times of my life." She emphasized the importance of discussing mental health side effects of weight-loss medications and encouraged others facing similar struggles to seek help.
Mar 23, 2026
U.S. overdose deaths declined 19% year-over-year to 72,108 for the 12 months ending September 2025, but the drug market is evolving with dangerous polydrug cocktails like "pink cocaine" and "rhino tranq" that are harder to detect and reverse. These synthetic blends combine fentanyl with stimulants, sedatives, and veterinary tranquilizers, creating new public health challenges as naloxone becomes less effective against complex overdoses.
Mar 23, 2026
The global generic drugs market reached $389 billion in 2024 and is projected to grow to $675 billion by 2033. In the U.S., generics account for 91% of prescriptions but only 18% of drug spending, saving over $373 billion annually. Biosimilar adoption remains below 20% despite some products reaching over 60% market share within three years.
Mar 18, 2026
A longitudinal study of 460,000 teenagers found that adolescent cannabis use increases the risk of developing bipolar and psychotic disorders by twofold, as well as raising risks for depression and anxiety.
Mar 18, 2026
The American Psychiatric Association will include biomarkers in the next DSM edition, though such markers remain unvalidated for routine clinical use. Research has spanned decades with limited adoption despite potential to guide treatment selection.
Mar 06, 2026
New clinical trials show single doses of psilocybin and LSD produce significant, lasting reductions in OCD and generalized anxiety disorder symptoms for up to 12 weeks, marking a potential shift from daily medication regimens.
Mar 04, 2026
Recent studies demonstrate brain stimulation therapies can accelerate depression treatment to five days and low-dose lithium may slow cognitive decline in seniors with mild cognitive impairment.
Mar 03, 2026
University of Melbourne receives $2.1 million for quantum-enabled brain-on-chip platform for neurological diseases, while Evogene partners with Queensland University of Technology on AI-driven cancer therapeutics targeting chemotherapy resistance.
Feb 23, 2026
A phase 2 trial found that a single intravenous dose of dimethyltryptamine (DMT) alongside psychotherapy significantly reduced major depressive disorder symptoms, with effects lasting up to 6 months.
Feb 18, 2026
The FDA has approved pitolisant tablets for treating cataplexy in pediatric patients aged 6 and older with narcolepsy, making it the only non-scheduled therapy approved for both pediatric and adult narcolepsy patients with or without cataplexy.
Feb 17, 2026
Recent studies reveal significant barriers in accessing mental health care for children and maternal health services, with nearly 25% of children's mental health needs going unmet and abortion restrictions linked to increased maternal deaths.
Feb 17, 2026
Compass Pathways reports positive Phase 3 results for synthetic psilocybin in treatment-resistant depression, while a Phase 2 trial demonstrates rapid antidepressant effects from single-dose DMT. Both studies show modest efficacy signals amid growing pharmaceutical interest in psychedelic compounds.
